Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Change in Account Payables (2022 - 2025)

Bioregenx (BRGX) has 4 years of Change in Account Payables data on record, last reported at -$78412.0 in Q3 2025.

  • For Q3 2025, Change in Account Payables rose 65.15% year-over-year to -$78412.0; the TTM value through Sep 2025 reached $252826.0, up 365.62%, while the annual FY2024 figure was $185784.0, 862.76% up from the prior year.
  • Change in Account Payables reached -$78412.0 in Q3 2025 per BRGX's latest filing, down from $39553.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $317462.0 in Q3 2023 and bottomed at -$270713.0 in Q2 2023.
  • Average Change in Account Payables over 4 years is $16331.9, with a median of $6916.0 recorded in 2022.
  • The widest YoY moves for Change in Account Payables: up 11107.7% in 2023, down 20347.79% in 2023.
  • A 4-year view of Change in Account Payables shows it stood at $2355.0 in 2022, then surged by 3686.33% to $89168.0 in 2023, then soared by 147.46% to $220653.0 in 2024, then crashed by 135.54% to -$78412.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$78412.0 in Q3 2025, $39553.0 in Q2 2025, and $71032.0 in Q1 2025.